Results of a Phase I Trial of Induction Cisplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib with Radiotherapy for Advanced Head and Neck Cancer

Authors

P. H. Ahn, Thomas Jefferson University and Hospitals
M. Machtay, University Hospitals Case Western Reserve University
P. R. Anné, Thomas Jefferson University and Hospitals
E. Wuthrick, Thomas Jefferson University and HospitalsFollow
W. M. Keane, Thomas Jefferson University and Hospitals
D. Cognetti, Thomas Jefferson University and HospitalsFollow
A. P. Dicker, Thomas Jefferson University and HospitalsFollow
R. S. Axelrod, Thomas Jefferson University and HospitalsFollow

Abstract

Background: A phase I trial of induction cisplatin, docetaxel, 5-FU and erlotinib (TPF-E) followed by cisplatin, bevacizumab and erlotinib (PA-E) with radiotherapy (XRT) for advanced head and neck cancer (HNC) was conducted.

American Society for Therapeutic Radiation Oncology (ASTRO) 52nd Annual Meeting October 31 - November 4, San Diego, CA

Recommended Citation

Ahn, P. H.; Machtay, M.; Anné, P. R.; Wuthrick, E.; Keane, W. M.; Cognetti, D.; Dicker, A. P.; and Axelrod, R. S. (2010) "Results of a Phase I Trial of Induction Cisplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib with Radiotherapy for Advanced Head and Neck Cancer," Bodine Journal: Vol. 3: Iss. 1, Article 22.
DOI: https://doi.org/10.29046/TBJ.003.1.021
Available at: https://jdc.jefferson.edu/bodinejournal/vol3/iss1/22